Biological
Rivogenlecleucel clinical trials
Also written BPX-501.
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Bellicum Pharmaceuticals (10) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rivogenlecleucel is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesTerminatedPhase 1Bellicum PharmaceuticalsNCT02231710Written as BPX-501 and Rimiducid
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedPhase 1/2Bellicum PharmaceuticalsNCT02065869Written as BPX-501 T cells
- Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDSTerminatedPhase 2/3Bellicum PharmaceuticalsNCT03699475Written as rivogenlecleucel
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedPhase 1/2Bellicum PharmaceuticalsNCT03733249Written as rivogenlecleucel
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingPhase 1/2Bellicum PharmaceuticalsNCT03301168Written as BPX-501 T cells
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruitingPhase 1/2Bellicum PharmaceuticalsNCT01744223Written as BPX-501 dose 1
- Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo TransplantActive, not recruitingPhase 1Bellicum PharmaceuticalsNCT03459170Written as BPX-501 T cells
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantActive, not recruitingPhase 1Bellicum PharmaceuticalsNCT02477878Written as BPX-501
- Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic MalignanciesWithdrawnPhase 1Bellicum PharmaceuticalsNCT02487459Written as BPX-501
- Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCTWithdrawnPhase 1Bellicum PharmaceuticalsNCT02786485Written as rivogenlecleucel
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnPhase 1Fred Hutchinson Cancer CenterNCT03807063Written as Rivogenlecleucel
Codes
What other systems call rivogenlecleucel · ClinicalTrials.gg INT016420
- UNII (FDA) E6349B696WRIVOGENLECLEUCELOne source FDA
- NCI Thesaurus C105395RivogenlecleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E6349B696W | RIVOGENLECLEUCEL | One source FDA |
| NCI Thesaurus | C105395 | Rivogenlecleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.